Identification of factors driving differences in cost effectiveness of first-line pharmacological therapy for uncomplicated hypertension

Canadian Journal of Cardiology

Volumn 26, Issue 5, 2010, Pages

  Klarenbach, Scott W ^a   McAlister, Finlay A ^a   Johansen, Helen ^b   Tu, Karen ^c   Hazel, Maureen ^a   Walker, Robin ^d   Zarnke, Kelly B ^d   Campbell, Norman R C ^d,e  

^a UNIVERSITY OF ALBERTA   (Canada)

^b STATISTICS CANADA   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF CALGARY   (Canada)

^e UNIVERSITY OF CALGARY   (Canada)

Author keywords

Clinical practice guidelines; Cost; Cost effectiveness; Hypertension; Pharmacotherapy

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; THIAZIDE DIURETIC AGENT;

ARTICLE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG COST; HEALTH CARE COST; HEART FAILURE; HUMAN; HYPERTENSION; PRACTICE GUIDELINE;

EID: 77952305696     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0828-282X(10)70383-4     Document Type: Article

References (32)

1. Public Health Agency of Canada. 2009 Tracking Heart Disease and Stroke in Canada. Ottawa: Public Health Agency of Canada, 2009.
2. Campbell NR, Chen G. Canadian Efforts to Prevent and Control Hypertension. Can J Cardiol 2010. (In press)
3. Tran K, Ho C, Noorani HZ, et al. Thiazide diuretics as first-line treatment for hypertension: Meta-analysis and economic evaluation. Technology report number 95. Ottawa: Canadian Agency for Drugs and Technologies in Health, 2007.
4. International Society of Hypertension. 〈www.ish-world.com〉 (Accessed on March 24, 2010).
5. Statistics Canada. Consumer Price Index for Canada (Health Care). 〈http://www.statcan.gc.ca/pub/62-001-x/62-001-x2010001-eng.htm〉 (Accessed on March 24, 2010).
6. Organization for Economic Co-operation and Development (OECD). Purchasing Power Parity and Exchange Rates. 〈http://stats.oecd.org/Index.aspx? datasetcode=SNA-TABLE4〉 (Accessed on March 24, 2010).
7. Canadian Agency for Drugs and Technologies in Health. Guidelines For the Economic Evaluation of Health Technologies, 3rd edn. Ottawa: Canadian Agency for Drugs and Technologies in Health, 2006.
8. Neumann PJ, Stone PW, Chapman RH, Sandberg EA, Bell CM. The quality of reporting in published cost-utility analyses, 1976-1997. Ann Intern Med 2000;132:964-972
9. National Collaborating Centre for Chronic Conditions. Management of hypertension in adults in primary care. NICE Clnical Guideline 18. London: Royal College of Physicians, 2006.
10. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 2003;289:2560-2572 (Pubitemid 37430158)
11. Whitworth JA. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003;21:1983-1992
12. McAlister FA, van Diepen S, Padwal RS, Johnson JA, Majumdar SR. How evidence-based are the recommendations in evidence-based guidelines? PLoS Med 2007;4:e250.
13. Briggs AH, O'Brien BJ. The death of cost-minimization analysis? Health Econ 2001;10:179-184
14. Government of Alberta Health and Wellness. Alberta Health and Wellness Drug Benefit List. Edmonton: Alberta Blue Cross, 2006.
15. Demers V, Melo M, Jackevicius C, et al. Comparison of provincial prescription drug plans and the impact on patients' annual drug expenditures. CMAJ 2008;178:405-409 (Pubitemid 351303282)
16. McAlister FA, Moerman S, Lewanczuk RZ. Cost of antihypertensive medications in Alberta. Can J Clin Pharmacol 1995;2:180-184
17. Khan NA, Hemmelgarn B, Herman RJ, et al. The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 - therapy. Can J Cardiol 2009;25:287-298
18. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-497
19. Friedman O, McAlister FA, Yun L, Campbell NR, Tu K. Antihypertensive drug persistence and compliance among newly treated elderly hypertensives in Ontario. Am J Med 2010;123:173-181
20. Bourgault C, Sénécal M, Brisson M, Marentette MA, Grégoire JP. Persistence and discontinuation patterns of antihypertensive therapy among newly treated patients: A population-based study. J Hum Hypertens 2005;19:607-613 (Pubitemid 41131661)
21. McInnis NH, Fodor G, Lum-Kwong MM, Leenen FH. Antihypertensive medication use and blood pressure control: A community-based cross-sectional survey (ON-BP). Am J Hypertens 2008;21:1210-1215
22. McAlister FA, Tu K, Majumdar SR, Padwal R, Chen G, Campbell NR. Laboratory testing in newly treated elderly hypertensive patients without co-morbidities: A population-based cohort study. Open Med 2007;1:E60-E67.
23. Tu K, Campbell NR, Duong-Hua M, McAlister FA. Hypertension management in the elderly has improved: Ontario prescribing trends, 1994 to 2002. Hypertension 2005;45:1113-1118
24. Tu K, Cauch-Dudek K, Chen Z. Comparison of primary care physician payment models in the management of hypertension. Can Fam Physician 2009;55:719-727
25. Wallace JF, Weingarten SR, Chiou CF, et al. The limited incorporation of economic analyses in clinical practice guidelines. J Gen Intern Med 2002;17:210-220 (Pubitemid 34603849)
26. Vawter L, Tong X, Gemilyan M, Yoon PW. Barriers to antihypertensive medication adherence among adults - United States, 2005. J Clin Hypertens (Greenwich) 2008;10:922-929
27. Australia NHF. Guide to management of hypertension 2008. National Heart Foundation of Australia, 2008.
28. Campbell NR, Khan NA, Hill MD, et al. 2009 Canadian Hypertension Education Program recommendations: The scientific summary - an annual update. Can J Cardiol 2009;25:271-277
29. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007;28:1462-1536
30. Haute Autorité de sante. [Management of adults with essential hypertension-2005 update-guidelines.] J Mal Vasc 2006;31:16-33.
31. Ogihara T, Kikuchi K, Matsuoka H, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res 2009;32:3-107.
32. Alberta Health and Wellness. Prescription Drug Program - Pharmacy Fee Reimbursement, 2009.